Diego Adrianzen-Herrera, MD, MS

Genomic and transcriptomic determinants of clinical outcomes in patients with AML and DNMT3A mutations - Blood Cancer Journal Blood Cancer Journal - Genomic and transcriptomic determinants of clinical outcomes in patients with AML and DNMT3A mutations

Genomic and transcriptomic determinants of clinical outcomes in patients with AML and DNMT3A mutations

www.nature.com/articles/s41...

Ph-Positive Acute Lymphoblastic Leukemia — 25 Years of Progress | NEJM Combined treatment with a tyrosine kinase inhibitor and blinatumomab has converted Ph-positive ALL, once the most deadly hematologic cancer, to a disease with long-term survival of 75 to 80%.

Ph-Positive Acute Lymphoblastic Leukemia — 25 Years of Progress | New England Journal of Medicine

www.nejm.org/doi/full/10....

The evolving landscape of epigenetic target molecules and therapies in myeloid cancers: focus on acute myeloid leukemia and myeloproliferative neoplasms - Leukemia Leukemia - The evolving landscape of epigenetic target molecules and therapies in myeloid cancers: focus on acute myeloid leukemia and myeloproliferative neoplasms

The evolving landscape of epigenetic target molecules and therapies in myeloid cancers

www.nature.com/articles/s41...

How I treat postimmunotherapy relapsed B-ALL Edited by Associate Editor Hervé Dombret, this How I Treat series highlights the clinical approach to high-risk subgroups of acute lymphoblastic leukemia (

How I treat postimmunotherapy relapsed B-ALL

ashpublications.org/blood/articl...

Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurin Key PointsFLT3-ITD MRD identifies patients at high relapse risk after intensive chemotherapy with midostaurin.Conversion from FLT3-ITD MRDneg to FLT3-ITD M

Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurin | Blood Advances | American Society of Hematology

ashpublications.org/bloodadvance...

How insurance companies degrade the patient-doctor relationship, by Helen Ouyang, my friend and exceptional physician-author
gift link www.nytimes.com/2024/12/08/o... @nytopinion.nytimes.com

Advanced biomarker testing for adults with acute myeloid leukemia or myelodysplastic syndrome

#myeloMATCH is the NCI’s #precisionmedicine trial in #myeloid cancer: advanced biomarker testing in newly diagnosed acute myeloid #leukemia (#AML) or #myelodysplastic syndrome (#MDS) & treatment substudies by the Alliance, Canadian Cancer Trials Group, @eaonc.bsky.social & SWOG. swog.org/myeloMATCH

Relevance of blast counts for genetic subclassification in MDS

www.nature.com/articles/s41...

8 days ago, ASH decided to join Bluesky. 🌤️ So far, we're enjoying fewer distractions & more meaningful connections. 💬 Engaging with our amazing #hematology and #hemeonc communities has never been easier.

We created an #ASH24 feed for you & we have more feeds coming soon: bit.ly/ASH24feed

#Hemesky

✋

Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine Key PointsELN 2017 and 2022 prognostic classifiers did not adequately stratify OS outcomes for patients with AML treated with venetoclax-azacitidine.A 4-ge

Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine

ashpublications.org/blood/articl...

Venetoclax and Hypomethylating Agent in Previously Untreated Higher‐Risk Myelodysplastic Syndromes and Genotype Signatures for Response and Prognosis: A Real‐World Study Click on the article title to read more.

Venetoclax + HMA for previously untreated Higher-Risk Myelodysplastic Syndromes and genotype signatures

onlinelibrary.wiley.com/doi/full/10....

Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine Key PointsELN 2017 and 2022 prognostic classifiers did not adequately stratify OS outcomes for patients with AML treated with venetoclax-azacitidine.A 4-ge

👇👇👇

Genetic risk stratification and outcomes in treatment-naive AML treated with venetoclax + azacitidine

ashpublications.org/blood/articl...

FDA approves revumenib for relapsed or refractory acute leukemia On November 15, 2024, the FDA approved revumenib (Revuforj, Syndax Pharmaceuticals, Inc.) for relapsed or refractory acute leukemia with a KMT2A translocation.

It’s always a great start to the day to learn we have one more drug to offer patients with r/r leukemia! 🎗️🩸💊 www.fda.gov/drugs/resour...

Very interesting 👇👇

Thank you for putting this together

Not many papers change the way I think about AML, but this exceptional work shows how cell states and genetics intertwine to mediate venetoclax resistance, unifying previous studies by identifying RAS-mutated LSCs that are primed to produce myeloid cells #hemesky 🩸🧪 www.nature.com/articles/s41...

New to Bluesky 🦋 Hello to all!